StockLens

Glenmark Pharmaceuticals Limited (GLENMARK) share price and analysis

GLENMARK last traded at ₹2,615.80 (-0.65%) on the NSE. Market cap ₹73,824 Cr (Mid cap), Pharma & Healthcare sector.

Overall rating: 4.6/10 (Average)

Long-term view: Neutral (watchlist). A mixed picture. Wait for better value or a clearer trend. Trade bias (next few weeks): Strong long. Trend and momentum are clearly pointing up.

Strengths of GLENMARK

Weaknesses of GLENMARK

Key numbers

NumberValueAssessmentNormal range
P/E (TTM)50.9Expensive vs peers37.0–49.3 (sector median 41.1)
Forward P/E27.1Profits expected to growbelow today's P/E (50.9) and near 41
Price / book6.58High2–6
EPS (TTM)₹51.41Profitableabove ₹0
Return on equity14.0%Average15%+ (below 10% is weak)
Debt / equity0.13Low debtbelow 1.0 (under 0.5 is great)
Net margin9.1%Average10%+ (below 5% is thin)
Operating margin16.9%Average20%+ strong, below 10% thin
Revenue growth-29.8%Shrinking10%+ a year (below 3% is weak)
Profit growth-56.8%Falling10%+ a year (falling is weak)
Dividend yield0.19%Small payout1.5%+ (none is fine for growth firms)
Current ratio1.69Comfortable1.5+ (below 1 is tight)
52W high₹2,714.004% below · near the highprice in the top 40% of its 52-week range
52W low₹1,818.00Price is 44% above it
50-DMA₹2,389.47Price 9.5% aboveprice above it = short-term uptrend
200-DMA₹2,254.89Price 16.0% aboveprice above it = long-term uptrend
1Y return+42.9%Beat the Nifty 50Nifty 50 did −0.4%
Beta0.27Steadier than the market0.8–1.3 (1 = moves with market)
Promoter / insider49.0%Moderate stake50%+ shows owner commitment
Institutions27.2%Moderate interest30%+ is strong
Analyst target₹2,659.551.7% upside · 11 analysts8%+ upside

Questions about GLENMARK

What is the share price of Glenmark Pharmaceuticals Limited (GLENMARK) today?

GLENMARK last traded at ₹2,615.80 (-0.65% on the day) on the NSE. Its 52-week range is ₹1,818.00 to ₹2,714.00. Prices are delayed and come from Yahoo Finance.

Is GLENMARK a good stock for the long term?

StockLens rates GLENMARK 4.6 out of 10 (Average) overall. Its long-term verdict is "Neutral (watchlist)": A mixed picture. Wait for better value or a clearer trend. Strengths: uptrend, bullish moving averages, low debt. Concerns: shrinking revenue, falling profits, expensive vs peers.

Is GLENMARK share overvalued?

GLENMARK trades at a P/E of 50.9 against a Pharma & Healthcare median of 41.1, which StockLens rates as "Expensive vs peers". Its price-to-book ratio is 6.58.

Is GLENMARK good for short-term trading?

The trade bias for the next few weeks is "Strong long": Trend and momentum are clearly pointing up. The price is 16.0% above its 200-day average and 14-day RSI is 67.

Which stocks are similar to GLENMARK?

Similar Pharma & Healthcare stocks of comparable size include Alkem Laboratories, Lupin, Biocon, Max Healthcare, Aurobindo Pharma. You can compare up to 4 of them side by side on StockLens.

About Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited, together with its subsidiaries, research, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides various products in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetes, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, and respiratory-metered dose inhaler, dry powder inhaler, and nasal sprays. Its product pipeline includes ISB 2001, a CD38 x BCMA x CD3 trispecific T cell engager, which is in Phase 1 clinical trial for indication of multiple myeloma; ISB 2301, a Multispecific Immune Cell Activator that is in preclinical trial for solid tumors; ISB 2302, a bispecific immune modulator with an indication for hematologic and solid tumors; and ISB 2501, a trispecific T-cell engager indicated for solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 2 clinical trial for the treatment of hidradenitis suppurativa; and telazorlimab and ISB 830-X8, a OX40 antagonist mAb for the treatment of atopic dermatitis. In addition, the company offers Ryaltris, fixed-dose nasal spray for the treatment of allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.

Stocks similar to GLENMARK

Compare GLENMARK with ALKEM, LUPIN, BIOCON

Educational information, not investment advice. Data from Yahoo Finance and NSE Indices; prices may be delayed.